Department of Nuclear Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, 03722, South Korea.
Department of Urology, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
Eur J Nucl Med Mol Imaging. 2024 May;51(6):1763-1772. doi: 10.1007/s00259-023-06585-7. Epub 2024 Jan 11.
[F]fluorodeoxyglucose ([F]FDG) positron emission tomography/computed tomography (PET/CT) has limitations in prostate cancer (PCa) detection owing to low glycolysis in the primary tumour. Recently, prostate-specific membrane antigen (PSMA) PET/CT has been useful for biochemical failure detection and radioligand therapy (RLT) guidance. However, few studies have evaluated its use in primary prostate tumours using PSMA and [F]FDG PET/CT. This study aimed to evaluate [F]PSMA-1007 and [F]FDG PET/CT for primary tumour detection and understand the association of metabolic heterogeneity with clinicopathological characteristics at staging and postoperatively.
This prospective study included 42 index tumours (27 acinar and 15 ductal-dominant) in 42 patients who underwent [F]PSMA-1007 and [F]FDG PET/CT and subsequent radical prostatectomy. All patients were followed for a median of 26 mo, and serum prostate-specific antigen levels were measured every 3 mo to evaluate biochemical failure. One-way analysis of variance, Tukey's multiple comparison test, and Fisher's exact test were performed.
All 42 index tumours were detected on [F]PSMA-1007 PET/CT, whereas only 15 were detected on [F]FDG PET/CT (62.3% vs. 37.7%, p < 0.0001). A high SUV for [F]PSMA-1007 was observed in tumours with high Gleason scores (GS 6-7 vs. GS 8-10; 12.1 vs. 20.1, p < 0.05). Tumours with [F]FDG uptake were mostly ductal dominant (acinar-dominant 4/27; ductal-dominant; 11/15, p < 0.001), with lower [F]PSMA-1007 uptake than tumours without [F]FDG uptake (SUVmax 16.58 vs. 11.19, p < 0.001). There were 16.6% (7/42) of patients with pStage IV in whom the primary tumours were [F]FDG positive. Biochemical failure was observed in 14.8% (4/27) of patients with [F]FDG negative tumours but in 53.3% (8/15) of patients with [F]FDG positive tumours (p = 0.013).
[F]PSMA-1007 PET/CT was superior to [F]FDG PET/CT in detecting primary PCa. In contrast, tumours with [F]FDG uptake are associated with larger size, a ductal-dominant type, and likely to undergo metastasis at staging and biochemical failure postoperatively.
由于原发性肿瘤中糖酵解水平较低,[F]氟代脱氧葡萄糖([F]FDG)正电子发射断层扫描/计算机断层扫描(PET/CT)在前列腺癌(PCa)检测方面存在局限性。最近,前列腺特异性膜抗原(PSMA)PET/CT 已被用于生化失败检测和放射性配体治疗(RLT)指导。然而,很少有研究使用 PSMA 和[F]FDG PET/CT 评估其在原发性前列腺肿瘤中的应用。本研究旨在评估[F]PSMA-1007 和[F]FDG PET/CT 在原发性肿瘤检测中的应用,并了解代谢异质性与分期和术后临床病理特征的相关性。
本前瞻性研究纳入了 42 名患者的 42 个指数肿瘤(27 个腺泡型和 15 个导管主导型),这些患者均接受了[F]PSMA-1007 和[F]FDG PET/CT 检查,随后进行了根治性前列腺切除术。所有患者的中位随访时间为 26 个月,每 3 个月测量一次血清前列腺特异性抗原水平,以评估生化失败情况。采用单因素方差分析、Tukey 多重比较检验和 Fisher 确切概率法进行分析。
42 个指数肿瘤均在[F]PSMA-1007 PET/CT 上被检测到,而只有 15 个在[F]FDG PET/CT 上被检测到(62.3%比 37.7%,p<0.0001)。高 Gleason 评分(GS 6-7 比 GS 8-10;12.1 比 20.1,p<0.05)的肿瘤[F]PSMA-1007 的 SUV 较高。摄取[F]FDG 的肿瘤主要为导管主导型(腺泡主导型 4/27;导管主导型 11/15,p<0.001),与无[F]FDG 摄取的肿瘤相比,摄取[F]PSMA-1007 的水平较低(SUVmax 16.58 比 11.19,p<0.001)。在 42 名患者中,有 16.6%(7/42)的患者为 pStage IV,其原发性肿瘤为[F]FDG 阳性。在[F]FDG 阴性肿瘤中,有 14.8%(4/27)的患者发生生化失败,但在[F]FDG 阳性肿瘤中,有 53.3%(8/15)的患者发生生化失败(p=0.013)。
[F]PSMA-1007 PET/CT 在检测原发性 PCa 方面优于[F]FDG PET/CT。相比之下,摄取[F]FDG 的肿瘤与更大的肿瘤体积、导管主导型和在分期时更有可能发生转移以及术后生化失败相关。